SDF-1α-Releasing Microspheres Effectively Extend Stem Cell Homing after Myocardial Infarction

Ischemic heart disease (IHD) is one of the main focuses in today's healthcare due to its implications and complications, and it is predicted to be increasing in prevalence due to the ageing population. Although the conventional pharmacological and interventional methods for the treatment of IHD presents with success in the clinical setting, the long-term complications of cardiac insufficiency are on a continual incline as a result of post-infarction remodeling of the cardiac tissue. The migration and involvement of stem cells to the cardiac muscle, followed by differentiation into cardiac myocytes, has been proven to be the natural process, though at a slow rate. SDF-1 alpha is a novel candidate to mobilize stem cells homing to the ischemic heart. Endogenous SDF-1 alpha levels are elevated after myocardial infarction, but their presence gradually decreases after approximately seven days. Additional administration of SDF-1 alpha-releasing microspheres could be a tool for the extension of the time the stem cells are in the cardiac tissue after myocardial infarction. This, in turn, could constitute a novel therapy for more efficient regeneration of the heart muscle after injury. Through this practical study, it has been shown that the controlled release of SDF-1 alpha from biodegradable microspheres into the pericardial sac fourteen days after myocardial infarction increases the concentration of exogenous SDF-1 alpha, which persists in the tissue much longer than the level of endogenous SDF-1 alpha. In addition, administration of SDF-1 alpha-releasing microspheres increased the expression of the factors potentially involved in the involvement and retention of myocardial stem cells, which constitutes vascular endothelial growth factor A (VEGFA), stem cell factor (SCF), and vascular cell adhesion molecules (VCAMs) at the site of damaged tissue. This exhibits the possibility of combating the basic limitations of cell therapy, including ineffective stem cell implantation and the ability to induce the migration of endogenous stem cells to the ischemic cardiac tissue and promote heart repair.

Automated summary

Ischemic heart disease (IHD) is a major concern in healthcare due to its implications and complications. Stem cell migration to the cardiac muscle is a slow process, but SDF-1 alpha can increase stem cell involvement. Administering SDF-1 alpha-releasing microspheres after myocardial infarction can promote heart repair and increase the expression of factors involved in stem cell retention and tissue repair.